

Supplementary Table 2. EMM changes from baseline to follow-ups at 3, 6, and 9 months in continuous glucose monitoring users

Outcomes	EMM (95% CI)		P value ^a
	Control group	Intervention group	
HbA1c, %			
3 months	-0.41 (-0.62 to -0.20)	-0.32 (-0.46 to -0.18)	0.656
6 months	-0.35 (-0.56 to -0.14)	-0.47 (-0.61 to -0.33)	0.710
9 months	-0.38 (-0.60 to -0.16)	-0.87 (-1.01 to -0.73)	0.063
GA, %			
3 months	-0.11 (-1.35 to 1.13)	-1.36 (-2.08 to -0.64)	0.602
6 months	-0.81 (-2.05 to 1.33)	-3.09 (-3.83 to -2.35)	0.277
9 months	-1.46 (-2.78 to -0.14)	-4.22 (-5.00 to -3.44)	0.042
FBS, mg/dL			
3 months	0.84 (-13.46 to 17.14)	7.53 (-2.57 to 17.63)	0.701
6 months	11.52 (-5.28 to 28.32)	-3.52 (-14.52 to 7.48)	0.381
9 months	-13.50 (-34.4 to -7.4)	-4.65 (-21.95 to 12.65)	0.559
GA/HbA1c ratio			
3 months	-0.01 (-0.05 to 0.03)	-0.03 (-0.07 to 0.01)	0.124
6 months	0.07 (0.02 to 0.12)	-0.01 (-0.06 to 0.04)	0.126
9 months	0.10 (0.05 to 0.15)	-0.12 (-0.17 to -0.07)	0.661

EMM changes from baseline to each follow-up were analyzed after adjusting for age, sex, and body mass index.

EMM, estimated marginal mean; CI, confidence interval; HbA1c, glycosylated hemoglobin; GA, glycoalbumin; FBG, fasting blood glucose.

^aP values for group × time interaction.